Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00053482 · ClinicalTrials.gov registry record · Phase 2
Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults
A Phase 2 study, sponsored by Emergent BioSolutions.
- Completed
- Registry status
- Phase 2
- Development phase
- 357
- Enrollment target
NCT00053482: Completed Phase 2 study, sponsored by Emergent BioSolutions.
NCT00053482 is a Phase 2 study that has completed, run by Emergent BioSolutions. The registered enrollment target is 357 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (168% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00053482, a Phase 2 study, has completed, sponsored by Emergent BioSolutions.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 357 participants
- Enrollment target
Study Summary
The objective of this study is to determine the minimum dose of ACAM2000 needed to produce a cutaneous reaction in at least 90% of a population of healthy adults at least 28 years of age and previously vaccinated against smallpox.
Primary Outcome
The neutralizing antibody response titers were determined by the Plaque-Reduction Neutralization Test (PRNT50)
Interventions
- BIOLOGICAL ACAM2000 Smallpox Vaccine
- BIOLOGICAL Vaccinia virus (calf lymph) smallpox vaccine: Dryvax®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 357 participants |
| Start Date | 2003-01 |
| Est. Completion | 2003-10 |
| Phase | Phase 2 |
What the finished NCT00053482 record still lists
NCT00053482 is an interventional study that assigns participants to a tested intervention. The registered 357 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (168% higher).
The record links to 0 conditions, and to 2 interventions - of which ACAM2000 Smallpox Vaccine is the first listed.
NCT00053482 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00053482 about?
NCT00053482 is a clinical study titled "Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults". The objective of this study is to determine the minimum dose of ACAM2000 needed to produce a cutaneous reaction in at least 90% of a population of healthy adults at least 28 years of age and previously vaccinated against smallpox.
What is the current status of trial NCT00053482?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 357 participants. The study started on 2003-01. Estimated completion is 2003-10.
What interventions are being tested in trial NCT00053482?
The interventions under investigation include: ACAM2000 Smallpox Vaccine (BIOLOGICAL), Vaccinia virus (calf lymph) smallpox vaccine: Dryvax® (BIOLOGICAL).
Who is sponsoring clinical trial NCT00053482?
This trial is sponsored by Emergent BioSolutions, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00053482's enrollment target sits among peer trials
357 127th of 2000 higher than 1,873 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06062888 · 357 participants · Phase 2
FFP In Traumatic BRAin INjury (FIT-BRAIN) Trial
- NCT06109766 · 357 participants · NA
Delivering Evidence-Based Parenting Services to Families in Child Welfare Using Telehealth
- NCT06231342 · 357 participants · NA
Endotracheal Tube (ETT) 180: Stylet-loaded Endotracheal Tube Rotation Before Insertion
- NCT06533826 · 357 participants · Phase 2
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia